Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

BACKGROUND: Malignant ascites (MA) is associated with poor prognosis and limited palliative therapeutic options. Therefore, quality of life (QoL) assessment is of particular importance to demonstrate new treatment value. Following the demonstration of the superiority of catumaxomab and paracentesis...

Descripción completa

Detalles Bibliográficos
Autores principales: Wimberger, P., Gilet, H., Gonschior, A-K., Heiss, M. M., Moehler, M., Oskay-Oezcelik, G., Al-Batran, S-E., Schmalfeldt, B., Schmittel, A., Schulze, E., Parsons, S. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403730/
https://www.ncbi.nlm.nih.gov/pubmed/22734013
http://dx.doi.org/10.1093/annonc/mds178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403730/
https://www.ncbi.nlm.nih.gov/pubmed/22734013
http://dx.doi.org/10.1093/annonc/mds178

Ejemplares similares